KRAS and neoplasm: Interestingly, of the 8 PDXs that demonstrated tumor regression, 6 (75%) were KRAS/BRAF mutant and PIK3CA wild-type, whereas the other 2 were either all wild-type, or all mutant for RAS/RAF or PI3KCA.